1. Home
  2. CORT vs CYTK Comparison

CORT vs CYTK Comparison

Compare CORT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CORT
  • CYTK
  • Stock Information
  • Founded
  • CORT 1998
  • CYTK 1997
  • Country
  • CORT United States
  • CYTK United States
  • Employees
  • CORT N/A
  • CYTK N/A
  • Industry
  • CORT Biotechnology: Pharmaceutical Preparations
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • CORT Health Care
  • CYTK Health Care
  • Exchange
  • CORT Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • CORT 7.6B
  • CYTK 8.0B
  • IPO Year
  • CORT N/A
  • CYTK 2004
  • Fundamental
  • Price
  • CORT $80.94
  • CYTK $67.12
  • Analyst Decision
  • CORT Strong Buy
  • CYTK Strong Buy
  • Analyst Count
  • CORT 5
  • CYTK 15
  • Target Price
  • CORT $139.00
  • CYTK $77.87
  • AVG Volume (30 Days)
  • CORT 639.6K
  • CYTK 1.9M
  • Earning Date
  • CORT 11-04-2025
  • CYTK 11-05-2025
  • Dividend Yield
  • CORT N/A
  • CYTK N/A
  • EPS Growth
  • CORT N/A
  • CYTK N/A
  • EPS
  • CORT 0.87
  • CYTK N/A
  • Revenue
  • CORT $741,172,000.00
  • CYTK $87,211,000.00
  • Revenue This Year
  • CORT $28.85
  • CYTK $363.61
  • Revenue Next Year
  • CORT $34.98
  • CYTK $64.33
  • P/E Ratio
  • CORT $91.92
  • CYTK N/A
  • Revenue Growth
  • CORT 17.92
  • CYTK 2609.26
  • 52 Week Low
  • CORT $49.00
  • CYTK $29.31
  • 52 Week High
  • CORT $117.33
  • CYTK $67.98
  • Technical
  • Relative Strength Index (RSI)
  • CORT 61.15
  • CYTK 60.62
  • Support Level
  • CORT $73.79
  • CYTK $59.85
  • Resistance Level
  • CORT $78.99
  • CYTK $67.98
  • Average True Range (ATR)
  • CORT 3.03
  • CYTK 2.88
  • MACD
  • CORT 0.61
  • CYTK -0.04
  • Stochastic Oscillator
  • CORT 95.41
  • CYTK 91.84

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: